News Releases

Media Contact: Tracy Vineis media@apellis.com (617) 420-4839

August 8, 2024 Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 1, 2024 Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
July 18, 2024 Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
July 9, 2024 Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
June 28, 2024 Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 10, 2024 SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 5, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
May 24, 2024 Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 14, 2024 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street